Global Peptide Therapeutics Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

What is the Peptide Therapeutics Market Size and Growth Rate?

• As per Data Bridge Market Research analysis, the peptide therapeutics market was valued at USD 64.49 billion in 2025 and is projected to reach USD 68.55 billion by 2033, growing at a CAGR of 6.30% from 2026 to 2033.
• The market is expanding due to the increasing prevalence of chronic and metabolic diseases, rising demand for targeted and highly effective therapies, growing adoption of peptide-based drugs for diabetes and obesity, and increasing investment in peptide drug discovery and development. Advancements in peptide synthesis, drug-delivery technologies, and manufacturing processes are further supporting market growth.
• Peptide therapeutics are peptide-based pharmaceutical products designed to provide targeted therapeutic effects for the treatment and management of various diseases. These therapies are used across applications such as metabolic disorders, cancer, cardiovascular disorders, neurological disorders, gastrointestinal disorders, pain, infectious diseases, renal disorders, dermatological disorders, and respiratory disorders. Technological advancements in peptide synthesis, recombinant DNA technology, oral and alternative delivery systems, and long-acting formulations are expanding the development and commercial applications of peptide therapeutics.

Market Size & Forecast

• Global Market Value (2025): USD 64.49 billion
• Expected Market Value (2033): USD 68.55 billion
• Forecast CAGR (2026–2033): 6.30%
• Leading Region in 2025: North America
• Fastest Growing Region: Asia-Pacific

What are the Major Takeaways of the Peptide Therapeutics Market?

• North America dominated the global peptide therapeutics market with a 38.34% revenue share in 2025, supported by established pharmaceutical and biotechnology infrastructure, strong adoption of peptide-based therapies, and significant investment in drug development.
• Asia-pacific is expected to be the fastest-growing region at a CAGR of 12.81% from 2026 to 2033, driven by expanding healthcare infrastructure, increasing prevalence of chronic diseases, and growing pharmaceutical and biotechnology investments.
• The branded peptide segment dominated the market with a 61.55% revenue share in 2025, supported by the strong commercial presence of established peptide therapeutics, high-value branded medicines, and continued investment in innovative peptide-based treatments.
• The metabolic disease segment represented the largest application segment with a 63.63% revenue share in 2025, driven by the increasing prevalence of diabetes and obesity and the widespread adoption of peptide-based therapies, particularly glp-1 receptor agonists.
• Parenteral administration dominated the peptide therapeutics market with an 83.99% revenue share in 2025, owing to the established use of injectable peptide therapies, high bioavailability, controlled dosing, and the widespread use of injectable treatments for metabolic, oncology, and other chronic conditions.
• Oral administration is expected to register a CAGR of 12.87% from 2026 to 2033, supported by advances in oral peptide delivery technologies and efforts to overcome peptide degradation and absorption limitations.

Report Scope and Peptide Therapeutics Market Segmentation

What is the Key Trend in the Peptide Therapeutics Market?

• The peptide therapeutics market is increasingly shifting toward oral and non-invasive peptide delivery technologies, as pharmaceutical companies seek to overcome the limitations associated with conventional injectable administration. Advances in formulation technologies, absorption enhancement, and controlled-release systems are supporting the development of once-daily oral peptide therapies for metabolic and chronic diseases.
• For instance, in march 2025, OPKO health and entera bio entered into a collaboration to advance opk-88006, an oral glp-1/glucagon peptide candidate, into clinical development. The program combines OPKO's long-acting oxyntomodulin analogue with entera bio's n-tab technology and is being developed as a once-daily tablet for obesity, metabolic, and fibrotic disorders. This development highlights the industry's movement toward replacing or complementing injectable peptide therapies with oral formulations.
• The market is also moving toward multi-mechanism peptide therapeutics and combination approaches for obesity and metabolic diseases. In march 2025, Roche entered into an exclusive collaboration with Zealand pharma to co-develop and co-commercialize Petrelintide, an amylin analogue, both as a standalone therapy and in combination with Roche's ct-388 incretin asset. The development reflects increasing interest in combining complementary mechanisms to address weight management and associated metabolic conditions.
• Overall, the peptide therapeutics market is increasingly shaped by the development of oral delivery, long-acting formulations, multi-mechanism therapies, ai-assisted peptide discovery, and improved dosing convenience. Recent partnerships involving Novo Nordisk, Roche, AstraZeneca, OPKO, Entera Bio, and specialized formulation companies demonstrate that manufacturers are focusing not only on discovering new peptide molecules but also on improving bioavailability, dosing frequency, administration route, therapeutic durability, and patient convenience.

What are the Key Drivers of the Peptide Therapeutics Market?

• The increasing prevalence of metabolic diseases, particularly obesity and diabetes, is a major driver of the peptide therapeutics market, as peptide-based therapies such as glp-1 receptor agonists have demonstrated significant clinical and commercial demand. The expansion of peptide therapies into weight management and cardiometabolic indications is encouraging pharmaceutical companies to increase investment in next-generation peptide molecules and alternative delivery technologies.
• For instance, in February 2026, Novo Nordisk and Vivtex announced a partnership to develop next-generation oral medicines for obesity and diabetes, using Vivtex's technologies to improve the bioavailability of peptide and protein therapeutics. Vivtex is eligible for payments of up to USD 2.1 billion, in addition to royalties on future product sales.
• Advancements in peptide drug-delivery technologies are supporting broader therapeutic adoption. This development highlights the industry's focus on improving the oral delivery and bioavailability of peptide therapeutics.
• Improved long-acting formulations are also driving innovation in peptide therapeutics, particularly for metabolic and chronic diseases where treatment adherence is important. Expansion of peptide manufacturing and supply-chain capabilities is supporting the growing demand for peptide-based medicines.
• Overall, the peptide therapeutics market is increasingly being driven by the rising burden of metabolic diseases, strong demand for glp-1-based therapies, development of oral and long-acting peptide formulations, advances in drug-delivery technologies, expansion of peptide manufacturing capacity, and increasing development of generic peptide medicines. These developments are shifting innovation beyond conventional injectable peptides toward oral, longer-acting, and more accessible peptide-based therapies.

What Factors Are Challenging the Growth of the Accelerometer-Based Digital Pen Market?

• Peptide stability and short biological half-life remain major challenges, as peptide molecules can be susceptible to enzymatic degradation, metabolic instability, aggregation, and rapid clearance. These characteristics can complicate formulation development and may require structural modification or specialized delivery technologies to maintain therapeutic activity.
• The industry is increasingly focusing on oral peptide delivery technologies to overcome injection-related limitations. Advanced drug-delivery technologies are becoming increasingly important for improving peptide bioavailability and formulation performance.
• For instance, in February 2026, Novo Nordisk and Vivtex announced a partnership to develop next-generation oral medicines for obesity and diabetes using Vivtex's technologies for identifying oral formulations of peptide and protein therapeutics with improved bioavailability.
• Manufacturing complexity and scalability can also constrain peptide therapeutic development, particularly when products require sophisticated synthesis, purification, formulation, and quality-control processes. The growing commercial demand for glp-1 and other peptide-based medicines is consequently increasing the importance of large-scale peptide manufacturing capacity.
• Overall, the peptide therapeutics market is increasingly shaped by challenges related to stability, bioavailability, route of administration, manufacturing scalability, and long-term dosing convenience. Recent collaborations involving oral delivery, ai-enabled peptide discovery, long-acting formulations, and expanded manufacturing capacity demonstrate how companies are attempting to address these limitations while developing differentiated peptide therapies.

How is the Peptide Therapeutics Market Segmented?

The Peptide Therapeutics market is segmented on the basis of type, application, and route of administration.

•  By Type

On the basis of type, the global peptide therapeutics market is segmented into branded peptide and generic peptide. The branded peptide segment dominated the market with a 61.55% share in 2025, supported by the strong commercial presence of established peptide therapies, continued innovation by pharmaceutical companies, and premium pricing associated with patented products.

The generic peptide segment is projected to register a CAGR of 8.25% from 2026 to 2033, driven by patent expirations, increasing availability of lower-cost alternatives, and growing demand for affordable peptide-based therapies.

•  By Application

On the basis of application, the global peptide therapeutics market is segmented into cancer, cardiovascular disease, metabolic disease, respiratory disease, infectious disease, and others. The metabolic disease segment dominated the market with a 63.63% revenue share in 2025, driven by the increasing prevalence of obesity and diabetes and the widespread adoption of peptide-based therapies, particularly glp-1 receptor agonists.

The gastrointestinal disease segment, under broader application classifications, is projected to register a CAGR of 11.85% from 2026 to 2033, reflecting increasing development of peptide therapies for gastrointestinal conditions.

•  By Route of Administration

On the basis of route of administration, the global peptide therapeutics market is segmented into oral administration, parenteral administration, pulmonary administration, mucosal administration, and injection administration. The parenteral administration segment dominated the market with an 83.99% revenue share in 2025, owing to the established use of injectable peptide therapies, reliable systemic exposure, controlled dosing, and high clinical adoption across metabolic, oncology, and other chronic diseases.

The oral administration segment is projected to register a CAGR of 12.87% from 2026 to 2033, supported by advances in oral peptide delivery technologies designed to overcome gastrointestinal degradation and poor bioavailability.

Which Region Holds the Largest Share of the Peptide Therapeutics Market?

• North America dominated the global peptide therapeutics market with the largest revenue share of 38.34% in 2025, supported by an established pharmaceutical and biotechnology ecosystem, strong research and development activity, advanced healthcare infrastructure, and high adoption of peptide-based therapies, particularly across metabolic and oncology indications.
• Asia-pacific is expected to be the fastest-growing region at a CAGR of 12.81% from 2026 to 2033, driven by expanding pharmaceutical manufacturing capabilities, increasing healthcare expenditure, growing adoption of peptide-based therapies, and rising research and development activities across China, India, Japan, South Korea, And Australia.

U.S. Peptide Therapeutics Market Insight

The u.s. peptide therapeutics market is supported by a well-established pharmaceutical and biotechnology ecosystem, extensive research and development capabilities, and strong clinical adoption of peptide-based medicines. Increasing demand for therapies targeting metabolic disorders, particularly diabetes and obesity, is contributing to market expansion. The presence of leading pharmaceutical companies, advanced healthcare infrastructure, and significant investment in innovative drug delivery technologies further supports market development. Growing interest in next-generation peptide therapies, improved formulation technologies, and expanding clinical pipelines is also creating opportunities for broader therapeutic applications across oncology, cardiovascular diseases, and other chronic conditions.

Canada Peptide Therapeutics Market Insight

The Canada peptide therapeutics market is supported by a well-developed healthcare system, growing pharmaceutical research capabilities, and increasing interest in advanced peptide-based treatments. Rising prevalence of metabolic disorders, cancer, and other chronic conditions is contributing to demand for innovative therapeutic approaches. The country’s strong academic and clinical research network supports the development and evaluation of novel peptide drugs. Increasing collaboration between biotechnology companies, research institutions, and pharmaceutical manufacturers is also supporting market expansion. In addition, advancements in peptide synthesis, drug delivery technologies, and formulation techniques are improving the therapeutic potential and clinical adoption of peptide-based medicines.

Germany Peptide Therapeutics Market Insight

Germany’s peptide therapeutics market is supported by a well-established pharmaceutical and biotechnology ecosystem, advanced clinical research infrastructure, and strong capabilities in biopharmaceutical development and manufacturing. The country has a substantial base of pharmaceutical companies, biotechnology firms, research institutions, and university hospitals involved in innovative drug development. Demand for peptide-based therapies is being strengthened by the growing focus on metabolic disorders, oncology, and other chronic conditions. Germany’s structured healthcare system, established reimbursement mechanisms, and emphasis on evidence-based treatment evaluation further support the adoption of advanced peptide therapies and continued investment in peptide research and development.

U.K. Peptide Therapeutics Market Insight

The U.K. Peptide therapeutics market is supported by a strong pharmaceutical research ecosystem, advanced healthcare infrastructure, and increasing investment in innovative drug development. Growing demand for targeted therapies for metabolic disorders, cancer, and other chronic conditions is supporting market expansion. The country benefits from established biotechnology and pharmaceutical companies, academic research institutions, and clinical development capabilities that facilitate peptide discovery and commercialization. Increasing interest in peptide-based therapies, including treatments for obesity and diabetes, is further contributing to market development. Advances in drug delivery technologies are also improving the potential for convenient peptide administration.

Asia-Pacific Peptide Therapeutics Market Insight

The Asia-pacific peptide therapeutics market is experiencing strong expansion, supported by increasing healthcare expenditure, improving pharmaceutical infrastructure, and rising investments in biotechnology and drug development. Growing awareness and adoption of advanced therapies for diabetes, obesity, cancer, and other chronic conditions are contributing to market development. The presence of expanding pharmaceutical manufacturing capabilities in countries such as China, India, Japan, And South Korea is further strengthening regional supply chains. In addition, increasing clinical research activities, government initiatives supporting life sciences, and rising demand for innovative treatment options are creating favorable opportunities for peptide therapeutics across the region.

China Peptide Therapeutics Market Insight

The China peptide therapeutics market is expanding due to increasing healthcare expenditure, growing pharmaceutical manufacturing capabilities, and rising demand for advanced therapies for chronic diseases. Strong government support for biotechnology and pharmaceutical innovation is encouraging domestic research and development of peptide-based medicines. Increasing prevalence of diabetes, obesity, and cancer is also supporting demand for targeted peptide therapies. In addition, improvements in peptide synthesis, drug delivery technologies, and clinical research capabilities are strengthening the country’s therapeutic development ecosystem. Expanding collaborations between domestic pharmaceutical companies and global biotechnology firms are further supporting market development.

Japan Peptide Therapeutics Market Insight

The Japan peptide therapeutics market is supported by a well-established pharmaceutical and biotechnology ecosystem, strong research capabilities, and increasing demand for targeted peptide-based treatments. Growing attention to metabolic disorders, particularly diabetes and obesity, is supporting the adoption of peptide therapies, while cancer and neurological applications are also contributing to clinical development. Pharmaceutical companies and research institutions are increasingly focusing on advanced peptide discovery, precision medicine, and innovative drug-delivery technologies. In addition, collaborations between Japanese pharmaceutical companies and global biotechnology firms are supporting the development and commercialization of next-generation peptide therapeutics.

Which are the Top Companies in Peptide Therapeutics Market?

The Peptide Therapeutics industry is primarily led by well-established companies, including:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• GlaxoSmithKline plc (UK)
• Novartis AG (Switzerland)
• Pfizer, Inc. (U.S.)
• Sanofi (France)
• Takeda Pharmaceutical Company Limited (Japan)
• Teva Pharmaceutical Industries Ltd, (Israel)
• Ipsen Pharma (France)
• AstraZeneca (UK)
• Lonza (Switzerland)
• Merck Sharp & Dohme Corp. (U.S.)
• Novo Nordisk A/S (Denmark)
• PolyPeptide Group (Switzerland)
• CordenPharma International (Germany)

What are Latest Developments in Peptide Therapeutics Market?

• In February 2026, Novo Nordisk partnered with Vivtex to develop next-generation oral medicines for obesity, diabetes, and related conditions. The collaboration focuses on technologies designed to improve the oral bioavailability of peptide and protein therapeutics, with Vivtex eligible for up to USD 2.1 billion in payments plus royalties.
• In January 2026, AstraZeneca entered into a strategic collaboration with CSPC Pharmaceuticals covering eight obesity and type 2 diabetes programs. The agreement includes access to an AI-driven peptide drug discovery platform and a once-monthly LiquidGel dosing technology for next-generation peptide therapies.
• In February 2026, OPKO Health and Entera Bio expanded their collaboration to advance an oral, long-acting PTH peptide tablet for hypoparathyroidism. The companies reported plans to accelerate development and target an IND filing in late 2026, supporting continued development of oral peptide delivery technologies.
• In July 2026, The U.S. FDA published 17 revised draft product-specific guidances covering generic peptide products, including semaglutide, liraglutide, glucagon, teriparatide, and pegcetacoplan. The development provides additional regulatory guidance for companies developing generic versions of peptide medicines.
• In June 2026, Novo Nordisk reported positive Phase 2 results for investigational zenagamtide (amycretin), a unimolecular peptide agonist targeting GLP-1 and amylin receptors. The company reported improvements in HbA1c and body weight in adults with type 2 diabetes and stated that the program would advance into Phase 3 trials.